- Home
- LPL vs PTGX Comparison
LPL vs PTGX Comparison
Compare LPL & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPL
- PTGX
- Stock Information
- Founded
- LPL 1985
- PTGX 2006
- Country
- LPL South Korea
- PTGX United States
- Employees
- LPL N/A
- PTGX N/A
- Industry
- LPL Industrial Machinery/Components
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- LPL Technology
- PTGX Health Care
- Exchange
- LPL Nasdaq
- PTGX Nasdaq
- Market Cap
- LPL 3.2B
- PTGX 2.7B
- IPO Year
- LPL 2004
- PTGX 2016
- Fundamental
- Price
- LPL $3.22
- PTGX $36.82
- Analyst Decision
- LPL Sell
- PTGX Strong Buy
- Analyst Count
- LPL 2
- PTGX 8
- Target Price
- LPL N/A
- PTGX $54.63
- AVG Volume (30 Days)
- LPL 261.7K
- PTGX 660.4K
- Earning Date
- LPL 01-22-2025
- PTGX 02-25-2025
- Dividend Yield
- LPL N/A
- PTGX N/A
- EPS Growth
- LPL N/A
- PTGX N/A
- EPS
- LPL N/A
- PTGX 2.68
- Revenue
- LPL $19,931,616,429.00
- PTGX $323,795,000.00
- Revenue This Year
- LPL $25.36
- PTGX $441.08
- Revenue Next Year
- LPL N/A
- PTGX N/A
- P/E Ratio
- LPL N/A
- PTGX $13.72
- Revenue Growth
- LPL 23.27
- PTGX 125.73
- 52 Week Low
- LPL $3.05
- PTGX $23.89
- 52 Week High
- LPL $5.66
- PTGX $48.89
- Technical
- Relative Strength Index (RSI)
- LPL 48.53
- PTGX 39.62
- Support Level
- LPL $3.05
- PTGX $35.03
- Resistance Level
- LPL $3.27
- PTGX $40.07
- Average True Range (ATR)
- LPL 0.08
- PTGX 1.56
- MACD
- LPL 0.01
- PTGX -0.04
- Stochastic Oscillator
- LPL 68.00
- PTGX 34.89
About LPL LG Display Co Ltd AMERICAN DEPOSITORY SHARES
LG Display Co Ltd is a South Korea-based company that is principally engaged in developing, manufacturing and selling TFT-LCD and OLED display panels. The company's products consist of panels for notebook computers, monitors, televisions, smartphones, tablets, and others. The company conducts direct sales through overseas subsidiaries in a number of countries, including the United States, Germany, Japan, Taiwan, China, and Singapore. These subsidiaries conduct sales activities and offer technical support to clients. The company generates the majority of its revenue from overseas markets, with the rest from South Korea.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.